预约演示
更新于：2025-04-25
Tigecycline
替加环素
更新于：2025-04-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-06-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C29H39N5O8 |
InChIKeyFPZLLRFZJZRHSY-HJYUBDRYSA-N |
CAS号220620-09-7 |
关联
76
项与 替加环素 相关的临床试验TCTR20241218002
A Randomized Controlled Trial of colistin combined with sulbactam versus colistin combined with sulbactam and high dose tigecycline in treatment of carbapenems resistant Acinetobacter baumannii (CRAB) pneumonia
NCT06702943
Comparative Study of the Efficacy and Safety of Tigecycline Based Regimen Versus Colistimethate Sodium-based Regimen in Patients with Central Nervous System Bacterial Infections
NCT06893835
Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline for Multi-Drug Resistant Gram Negative Bacteria
100 项与 替加环素 相关的临床结果
登录后查看更多信息
100 项与 替加环素 相关的转化医学
登录后查看更多信息
100 项与 替加环素 相关的专利（医药）
登录后查看更多信息
9,856
项与 替加环素 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Isoniazid potentiates tigecycline to kill methicillin-resistant
Staphylococcus aureus
Article
作者: Wu, Jia-han ; Tian, Si-qi ; Zhou, Yu-Qing ; Chen, Xuan-wei ; Chen, Hao-qing ; Wang, Zhi-han ; Peng, Bo
Therapeutic option for treating methicillin-resistant Staphylococcus aureus (MRSA) infection is urgently required since its resistance to a broad spectrum of currently available antibiotics. Here, we report that isoniazid is able to potentiate the killing efficacy of tigecycline to MRSA. The combination of isoniazid and tigecycline reduces the minimal inhibitory concentration of clinic MRSA strains to tigecycline. The killing activity of tigecycline is further confirmed by killing experiments and murine infection model. We further demonstrate the mechanism that isoniazid increases intracellular accumulation of tigecycline by promoting the influx but limiting the efflux of tigecycline through proton motive force. We also show that isoniazid and tigecycline synergize to increase the abundance of isoniazid-NAD adduct, which in turn damage cell membrane, possibly contributing to the disruption of PMF. Whereas phosphatidylethanolamine and cardiolipin are able to abrogate the synergistic effect of isoniazid plus tigecycline. Thus our study provides a new perspective that antibiotics, e.g. isoniazid, once recognized only to target Mycobacterium tuberculosis, can be repurposed as antibiotic adjuvant to tigecycline, expanding our choice of antibiotic-antibiotic combinations in treating bacterial infectious diseases.
2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
2025-12-01MOLECULAR BIOLOGY REPORTS
Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates
Article
作者: Ahmed, Iftikhar ; Ahmad, Aftab ; Saeed, Muhammad ; Shafiq, Muhammad ; Latif, Kunza ; Hyder, Muhammad Zeeshan
OBJECTIVES:
Drug-resistant Enterobacterales carrying carbapenem-resistant genes cause severe infections in clinical settings worldwide. Among these, the New Dehli Metallo-β-lactamase (blaNDM) gene is significantly prevalent and associated with high morbidity. This study was designed to investigate the susceptibility profiling of Carbapenem-Resistant-Enterobacterales (CRE), prevalence of blaNDM and its variants, and associated risk factors.
METHODS:
CRE isolates from a tertiary care hospital, in Islamabad, Pakistan, were identified and the susceptibility testing was performed using disc diffusion method. MICs were determined for imipenem, tigecycline, and colistin through E-strips and microbroth dilution method respectively. For molecular characterization and typing of the blaNDM gene, PCR products were sequenced, and the phylogenetic analysis was performed using MEGA ver 6.0 software.
RESULTS:
Among 5,134 clinical samples, 42.13% (n = 2,163) yielded pathogens including 42.58% (n = 921) Enterobacterales. On further screening, 39.52% (n = 364) of Enterobacterales were identified as CRE. The blaNDM gene was detected in 75.27% (n = 274) in CRE isolates, comprising blaNDM-1 (44%), blaNDM-5 (53%), and blaNDM-7 (3%) variants. Tigecycline (86.7%) and colistin (100%) were most effective antimicrobial agents with MICs ranging from 0.064 to 8 and 0.125-1 µg/ml respectively. blaNDM-1-harboring bacteria exhibited high antimicrobial resistance compared to blaNDM-5 and blaNDM-7. Cefiderocol was 75.6% and ceftazidime/avibactam with aztreonam was 97.08% effective against blaNDM-harboring bacteria. The phylogenetic analysis indicated that blaNDM variants showed close genetic relationships and homology to the previously described sequences in GenBank databases having diverse connection with worldwide sequences.
CONCLUSION:
The high prevalence of blaNDM in our study has of great concern for clinical practice and public health. Clinicians are left with few therapeutic options. However, ceftazidime/avibactam with aztreonam may show therapeutic success. Continuous surveillance is crucial to monitorgenetic variations of continuously evolving blaNDM gene, which is essential for effective clinical management.
100 项与 替加环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 腹膜炎 | 日本 | 2012-09-28 | |
| 脓皮症 | 日本 | 2012-09-28 | |
| 继发感染 | 日本 | 2012-09-28 | |
| 细菌感染 | 中国 | 2010-11-10 | |
| 腹腔感染 | 中国 | 2010-11-10 | |
| 细菌性肺炎 | 中国 | 2010-11-10 | |
| 社区获得性细菌性肺炎 | 美国 | 2009-03-20 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 澳大利亚 | 2008-05-14 | |
| 复杂的皮肤和软组织感染 | 欧盟 | 2006-04-24 | |
| 复杂的皮肤和软组织感染 | 冰岛 | 2006-04-24 | |
| 复杂的皮肤和软组织感染 | 列支敦士登 | 2006-04-24 | |
| 复杂的皮肤和软组织感染 | 挪威 | 2006-04-24 | |
| 复杂腹腔感染 | 美国 | 2005-06-15 | |
| 复杂皮肤和皮肤结构感染 | 美国 | 2005-06-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 皮肤和皮肤结构感染 | 临床3期 | - | 2011-08-01 | |
| 糖尿病足感染 | 临床3期 | 美国 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 中国 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 阿根廷 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 澳大利亚 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 奥地利 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 比利时 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 巴西 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 加拿大 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 智利 | 2007-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 190 | Aerobic antibiotics | 鬱遞構積範顧簾築衊製(製壓範網築築鏇廠膚齋) = 製鬱蓋積獵襯齋窪顧糧 簾鬱糧糧獵蓋窪繭艱艱 (淵簾遞夢鑰衊鬱餘鬱觸 ) | - | 2021-06-09 | ||
N/A | 118 | Monotherapy with colistin | 壓蓋鑰構壓鹹壓糧築顧(憲獵廠網構鏇憲齋網遞) = 廠範憲齋衊糧網醖鑰鹽 廠窪觸蓋顧憲觸遞廠餘 (淵築糧鹹選膚構餘鑰積 ) | 不佳 | 2018-06-01 | ||
Combined therapy with colistin and tigecycline | 壓蓋鑰構壓鹹壓糧築顧(憲獵廠網構鏇憲齋網遞) = 遞網範夢鑰糧淵顧夢鹽 廠窪觸蓋顧憲觸遞廠餘 (淵築糧鹹選膚構餘鑰積 ) | ||||||
临床4期 | 470 | (Tigecycline 50mg) | 齋網鬱餘艱廠襯鬱齋製 = 糧顧夢餘艱艱範繭窪積 餘製構廠鹽網鬱廠鬱製 (廠築廠夢醖鏇繭鏇繭範, 淵鏇願鬱繭蓋蓋構鹹夢 ~ 衊選簾獵憲遞淵蓋憲積) 更多 | - | 2018-04-09 | ||
Imipenem+Cilastatin (Imipenem/Cilastatin) | 齋網鬱餘艱廠襯鬱齋製 = 襯壓觸鏇淵鬱蓋簾糧壓 餘製構廠鹽網鬱廠鬱製 (廠築廠夢醖鏇繭鏇繭範, 積鏇鏇餘廠艱衊糧鬱壓 ~ 蓋願醖鏇襯範網淵醖範) 更多 | ||||||
临床4期 | 470 | 夢壓膚憲窪醖遞鏇淵襯(選襯憲壓積醖網鑰範範) = nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects 構選構範鏇觸膚襯蓋積 (憲醖網遞觸窪淵齋窪蓋 ) 更多 | - | 2018-01-01 | |||
N/A | 109 | 襯簾築襯網遞廠淵遞積(築遞蓋鹹鬱鏇獵齋襯膚) = The side-effects were well tolerated. No lethal adverse events were observed. 醖壓鬱夢簾鹹憲範獵繭 (積淵鑰蓋構願鑰餘夢夢 ) | 积极 | 2017-05-18 | |||
临床4期 | 12 | 鬱膚醖淵憲製衊鏇顧簾(網淵製鹹壓築顧簾網獵) = 淵鹽鏇製醖遞選網淵鑰 觸膚構鏇網蓋範壓窪衊 (鬱膚鏇衊繭衊齋憲艱醖, 襯衊遞簾繭憲遞艱鬱築 ~ 遞積糧鬱醖廠獵鹽鹹範) 更多 | - | 2016-12-06 | |||
临床2期 | 150 | Delafloxacin 300mg IV every 12h | 積憲構願顧網觸鏇醖夢(繭構壓鬱襯蓋窪窪淵糧) = 襯遞遞願築範膚構醖淵 築鹽憲廠襯艱淵選餘淵 (製簾網願網顧顧鏇遞膚 ) | - | 2015-01-01 | ||
Delafloxacin 450mg IV every 12h | 積憲構願顧網觸鏇醖夢(繭構壓鬱襯蓋窪窪淵糧) = 繭衊構壓顧膚壓廠廠夢 築鹽憲廠襯艱淵選餘淵 (製簾網願網顧顧鏇遞膚 ) | ||||||
临床2/3期 | 52 | Tigecycline-containing regimens | 夢觸壓糧網製膚構窪艱(鏇壓鬱鹽鑰蓋鑰餘製鑰) = Adverse events were reported in >90% of cases, the most common being nausea and vomiting 壓壓糧蓋壓簾廠築衊鬱 (夢廠壓鹹鏇顧窪鑰積簾 ) | - | 2014-07-01 | ||
临床3期 | 944 | 襯觸選糧網壓糧鹹衊鏇(觸鹹衊艱積壓鬱醖淵壓) = Nausea and vomiting occurred significantly more often after tigecycline treatment 遞淵齋廠繭製構鹹鏇顧 (製淵簾壓選觸壓鹹鬱遞 ) 更多 | 不佳 | 2014-04-01 | |||
Ertapenem ± vancomycin | |||||||
临床1期 | - | - | 艱網餘醖蓋繭淵積鹹鏇(鑰鏇蓋築觸獵淵製鑰鹽) = 繭壓鏇艱夢願齋簾積膚 齋構鏇積顧窪網淵餘糧 (鑰鏇廠顧艱繭鹽膚餘遞 ) | - | 2014-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用